2024欧洲肿瘤学会（ESMO 2024）年会即将来袭，此次会议将于欧洲中部夏令时间（CET）9月13日-17日在西班牙巴塞罗那举行。
近日，ESMO大会官方已公布Late-breaking abstracts（LBA）的摘要题目及作者信息。【肿瘤资讯】特别整理本次公布的泌尿肿瘤相关专场的LBA重磅研究标题，以飨读者。
Presidential Symposium I: 改变临床的试验
LBA1
A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3
EORTC-GUCG 1333/PEACE-3研究首次结果：一项随机多中心开放标签III期试验，比较恩扎卢胺与镭-223（Ra223）联合恩扎卢胺在无症状或轻度症状的骨转移去势抵抗性前列腺癌患者中的疗效
讲者：Silke Gillessen (Bellinzona, Switzerland)
Proffered paper session 1: 泌尿肿瘤, 非前列腺癌
专场时间：2024年9月13日，14:00 - 15:30
专场主席：Dana Rathkopf (New York, United States of America, NY)，Gerhardt Attard (London, United Kingdom)
专场地点：Granada Auditorium - Hall 6
LBA73
Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Following 1 or 2 Prior Therapies including an Immune Checkpoint Inhibitor (ICI) – Results of the Phase III TiNivo-2 Study
III期TiNivo-2研究结果：在既往接受过1或2线治疗（包括免疫检查点抑制剂）的肾细胞癌患者中对比Tivozanib联合纳武利尤单抗和Tivozanib单药治疗
讲者：Toni K. Choueiri (Boston, United States of America)
LBA74
Final analysis of the phase 3 LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
III期LITESPARK-005研究的最终分析：在既往接受过治疗的晚期透明细胞肾细胞癌患者中比较贝祖替芬与依维莫司
讲者：Brian I. Rini (Nashville, United States of America, OH)
LBA75
Prospective randomised phase-II trial of Ipilimumab/Nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
SUNNIFORECAST试验结果：一项前瞻性随机II期试验，在非透明细胞肾细胞癌中比较伊匹木单抗/纳武利尤单抗治疗与标准治疗
讲者：Lothar Bergmann (Frankfurt am Main, Germany)
Proffered paper session 2 :泌尿肿瘤, 非前列腺癌
专场时间：2024年9月16日，08:30-10:00
专场地点：Sevilla Auditorium - Hall 2
LBA84
TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): interim analysis of SunRISe-4 (SR-4)
SunRISe-4 (SR-4)研究中期分析：TAR-200联合Cetrelimab或Cetrelimab单药作为新辅助治疗方用于不适合或拒绝接受新辅助顺铂化疗的肌层浸润性膀胱癌患者
讲者：Andrea Necchi (Milan, Italy)
Proffered paper session: 泌尿肿瘤, 前列腺癌
专场时间：2024年9月15日，14:45-16:15
专场地点：Valencia Auditorium - Hall 5
LBA65
Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)
177Lu-PNT2002在雄激素受体通路抑制剂（ARPI）治疗后进展的PSMA阳性转移性去势抵抗性前列腺癌患者中的疗效（SPLASH）。
讲者：Oliver Sartor (Rochester, United States of America, LA)
LBA66
UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA-617 and Docetaxel (D) versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
UpFrontPSMA: 一项序贯使用177Lu-PSMA-617与多西他赛对比多西他赛单药治疗转移性激素敏感性前列腺癌的随机II期研究
讲者：Arun A. Azad (Melbourne, Australia, British Columbia)
LBA67
Cabozantinib (C) Plus Atezolizumab (A) Versus 2nd Novel Hormonal Therapy (NHT) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Final Overall Survival (OS) Results of the Phase 3, Randomized, CONTACT-02 Study
3期、随机、CONTACT-02研究的最终总生存期结果：在转移性去势抵抗性前列腺癌患者中比较卡博替尼联合阿替利珠单抗治疗与二代新型激素疗法
讲者：Neeraj Agarwal (Salt Lake City, United States of America)
Mini oral session: 泌尿肿瘤, 前列腺癌
专场时间：2024年9月16日，10:15-11:45
专场地点：Madrid Auditorium - Hall 2
LBA68
Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARANOTE trial
III期ARANOTE试验：达罗他胺联合雄激素剥夺治疗（ADT）在转移性前列腺癌敏感性患者中的疗效和安全性
讲者：Fred Saad (Montreal, Canada)
LBA69
Prostate cancer efficacy results from a randomised phase 3 evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer
一项随机、III期研究，评估经皮雌二醇（tE2）与促黄体生成素释放激素激动剂（LHRHa）用于非转移性前列腺癌雄激素抑制的疗效结果
讲者：Ruth E. Langley (London, United Kingdom)
LBA70
Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE
转移性激素敏感性前列腺癌（mHSPC）患者在雄激素剥夺治疗（ADT）基础上添加二甲双胍：多组、多阶段随机化平台试验STAMPEDE的总生存期结果
讲者：Silke Gillessen (Bellinzona, Switzerland)
LBA71
Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in Metastatic Castration Resistant Prostate Cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)
比较镭223-多西他赛与多西他赛-镭223的不同序贯治疗方案在转移性去势抵抗性前列腺癌的开放标签、多中心随机试验，并进行前瞻性生物标志物评价（RAPSON研究）
讲者：Vincenza Conteduca (Foggia, Italy)
LBA72
Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
纳武利尤单抗 3mg/kg 和伊匹木单抗 1mg/kg（nivo3/ipi1）在分子水平筛选的转移性去势抵抗性前列腺癌患者中的应用
讲者：Niven Mehra (Nijmegen, Netherlands, Surrey)
Mini oral session: 泌尿肿瘤, 非前列腺癌
专场时间：2024年9月16日，08:30-10:00
专场地点：Bilbao Auditorium - Hall 2
LBA85
TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non–muscle-invasive bladder cancer (HR NMIBC): updated results from SunRISe-1 (SR-1)
SunRISe-1 (SR-1)更新结果：TAR-200联合或不联合Cetrelimab与Cetrelimab单药治疗卡介苗无应答（BCG UR）高危非肌层浸润性膀胱癌患者
讲者：Michiel S. Van der Heijden (Amsterdam, Netherlands)
LBA76
Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC) -A randomized, open-label, phase III study (ETER100)
安罗替尼联合抗PD-L1抗体贝莫苏拜单抗（TQB2450）对比舒尼替尼在晚期肾细胞癌中的一线治疗——一项随机、开放标签、III期研究（ETER100）
讲者：盛锡楠 (北京, 中国)
LBA77
Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma. Preliminary results of the randomized phase 2 TACITO trial.
随机II期TACITO试验初步结果：粪便微生物移植（FMT）与安慰剂在接受帕博利珠单抗联合阿昔替尼治疗的转移性肾细胞癌患者中的比较
讲者：Chiara Ciccarese (Rome, Italy)
如有遗漏，敬请留言补充！
排版编辑：肿瘤资讯-CY
苏公网安备32059002004080号
